What Matricis.ai does

Matricis.ai is a French healthcare technology company developing EndomAI, a medical-grade AI copilot designed to assist radiologists in detecting and mapping endometriosis from pelvic MRI scans. Founded as a spin-off of Inria (the French National Institute for Research in Digital Science and Technology) and AP-HP (Assistance Publique–Hôpitaux de Paris, Europe's largest hospital system), the company targets the average 7–10 year diagnostic delay for endometriosis, a condition affecting approximately 190 million people globally, including roughly 1 in 10 women of reproductive age.

The core technology is a deep learning-based computer vision system trained on what the company describes as the world's largest pelvic MRI datasets, assembled from multi-center clinical data across three continents and annotated by expert pelvic imaging radiologists. EndomAI is intended to improve the sensitivity and specificity of lesion detection, diagnostic consistency across radiologists, and radiologist confidence when communicating findings to referring OB/GYN physicians; all interpretations remain under board-certified radiologist supervision. The platform is currently being validated through clinical studies, with FDA clearance targeted for Q4 2026.

Commercially, Matricis.ai operates a B2B software licensing model (subscription/recurring) targeting radiology departments at hospitals and outpatient imaging centers, with pricing not publicly disclosed and quote-based commercial pricing expected following FDA clearance. Distribution today is limited to clinical pilot programs: the first U.S. clinical pilot launched in April 2026 with SimonMed Imaging (one of the largest U.S. outpatient imaging providers), enrolling approximately 200 patients at select centers. The company is headquartered in France (Paris), has 1–10 employees (four named core team members: Co-founder & CEO Raphaelle Taub, Co-founder & COO Elise Mekkaoui, Head of Radiology Laure Gracia, CTO Alexandre Kempf), and has received non-dilutive backing from AGORANOV (2023) and selection into the 2026 Springboard Women's Health Accelerator cohort.

Name

Matricis.ai

Legal name

Matricis.ai

Website

https://matricis.ai

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Short description

Matricis.ai is a French healthcare technology company developing EndomAI, a deep-learning AI copilot that assists radiologists in detecting endometriosis from pelvic MRI scans. It sells B2B software to hospitals and imaging centers and is running a U.S. clinical pilot with SimonMed Imaging ahead of its targeted Q4 2026 FDA clearance.

Ownership category

akta.pro rank

Product category

Medical Imaging AI Software

NAICS

Diagnostic Imaging Centers (621512), Computer Systems Design and Related Services (54151)

akta.pro primary industry

Radiology AI, CAD & Advanced Visualization Software (HLAHABAJ)

akta.pro secondary industries

End-to-End Enterprise AI Platforms (MLOps & Model Lifecycle Management) (HDAEANAA), SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG), Medical Imaging AI (HDAAAEAH)

Keywords

• Medical imaging AI
• Radiology software
• Endometriosis detection
• Pelvic MRI analysis
• Diagnostic AI platform

Headquarters

HQ city

Paris

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. B2B Software Licensing: B2B licensing model targeting healthcare institutions including imaging centers and hospitals. AI-powered medical imaging software licensed to radiology departments. Commercial deployment planned following FDA clearance anticipated in Q4 2026.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Matricis.ai develops EndomAI, a medical-grade AI copilot that assists radiologists in detecting and mapping endometriosis on pelvic MRI scans. The deep learning models are trained on multi-center pelvic MRI datasets from three continents, annotated by expert pelvic imaging radiologists, and designed to improve sensitivity and specificity of endometriosis detection. The platform is targeted at radiology departments at hospitals and outpatient imaging centers for clinical use.

Product overview

Matricis.ai is a French healthcare technology company and spin-off of Inria and AP-HP, offering a single unified product called EndomAI. EndomAI is a medical-grade AI copilot designed specifically to assist radiologists with women's pelvic MRI reads, focusing on the detection and mapping of endometriosis. The company is currently conducting its first U.S. clinical pilot with SimonMed Imaging and is pursuing FDA clearance planned for Q4 2026.

Differentiator

Problem solved

Functional benefit

Brands

• EndomAI: AI-powered platform designed to assist radiologists in detecting endometriosis from MRI scans, improving diagnostic accuracy and supporting women's pelvic MRI reads.

Products and services

• EndomAI Medical-grade AI copilot that assists radiologists in detecting and mapping endometriosis on pelvic MRI scans, improving sensitivity and specificity of lesion detection and supporting diagnostic consistency for women's pelvic MRI reads. Targeted at radiology departments at hospitals, outpatient imaging centers, and specialty clinics, with FDA clearance planned for Q4 2026.

Quantifiable outcome

• Average diagnostic delay reduced from 7-10 years through earlier and more accurate AI-assisted detection
• +2 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

Partnerships

Four partnerships are on record, tiered flagship, core and supporting.

• SimonMed ImagingflagshipStrategic or Co-development Partner · 10 April 2026Matricis.ai launched first U.S. clinical pilot of EndomAI with SimonMed Imaging, one of the largest outpatient imaging providers in the United States. The partnership enables evaluation of AI-assisted endometriosis detection at select SimonMed centers, with approximately 200 patients enrolled in initial phase. All interpretations remain under supervision of board-certified radiologists. Collaboration aims to accelerate clinical validation and regulatory approval for commercial deployment.
• Inria (French National Institute for Research in Computer Science and Automation)coreOthersMatricis.ai is a spin-off of Inria, the French National Institute for Research in Computer Science and Automation. The company's AI technology originated from Inria research.
• AP-HP (Assistance Publique-Hopitaux de Paris)coreOthersMatricis.ai is a spin-off of AP-HP, the largest hospital system in Europe. The company developed its EndomAI platform in collaboration with leading hospitals.
• Springboard EnterprisessupportingGTM or Marketing PartnerMatricis.ai was selected for the 2026 Springboard Women's Health Accelerator cohort, gaining access to mentorship, networking, and resources for women's health technology companies.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Emerging players

• iSono Health: AI-augmented women's imaging (automated breast ultrasound) sold to clinics. Comparable as a women's-health-specific AI imaging vendor with a similar clinical evidence and regulatory timeline.

Direct peers

• Viz.ai: Specialty-focused radiology AI (originally stroke, now expanding) sold to hospital systems as workflow software. Highly comparable in being a single-indication imaging AI that expanded into adjacent neurovascular use cases via enterprise sales.
• Arterys (Tempus): Cloud-native medical imaging AI platform with FDA-cleared cardiac and lung MRI/CT products, now part of Tempus. Comparable as an enterprise SaaMD platform that ingests MRI and assists radiologist interpretation.
• AIDOC: AI radiology SaaMD platform with multiple FDA-cleared algorithms for CT and MRI triage and detection. Closely comparable to Matricis.ai in product category (AI imaging SaMD for radiologists), regulatory pathway, and B2B enterprise licensing model.
• Therapixel: French AI medical imaging company with mammography AI product (MIA), FDA-cleared and deployed in U.S. breast imaging centers. Closely comparable as a French-origin women's imaging AI with U.S. regulatory pathway and imaging-center customers.
• Qure.ai: AI for radiology across multiple specialties (head CT, chest, musculoskeletal) with FDA-cleared products and global hospital deployments. Comparable in being a multi-indication medical imaging AI serving radiology departments.
• Blackford Analysis: Radiology AI platform that curates and deploys multiple third-party AI algorithms to hospital imaging departments. Comparable as an infrastructure layer through which specialty AI like EndomAI is sold to radiology.
• Annalise.ai: Comprehensive radiology AI covering chest X-ray, CT, and MRI with deep learning models sold to hospital networks. Comparable in targeting radiologist interpretation across multiple modalities with a B2B SaaMD motion.

Broad incumbents

• DeepHealth (RadNet): Subsidiary of RadNet, one of the largest U.S. outpatient imaging networks, commercializing AI across the radiology workflow. Comparable in selling AI directly into outpatient imaging centers and owning both the technology and the imaging delivery infrastructure.
• Siemens Healthineers (AI-Rad Companion): Imaging equipment OEM with a growing portfolio of AI-Rad Companion radiology AI applications integrated into MRI scanners and PACS. Comparable as a large, established vendor that incumbents could compete against — or partner with — for women's pelvic MRI AI.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Matricis.ai